The model comprises of access to
- Funding for research and possibly up to IND stage
- Disease expertise
- World-class drug discovery and development resources at Evotec
- Clinical, regulatory, business, and commercial guidance from Novo Nordisk
- Consultations with respective technology transfer offices and a dedicated LAB eN² Collaboration Lead to apply for funding
LAB eN² builds on Evotec and Novo Nordisk´s complimentary expertise in discovering and developing first- and best-in-class therapeutics.
Evotec is a recognized world leader in translational drug discovery with the pre-clinical capabilities to develop a wide range of different drug modalities (i.e. small molecules, biologics, nucleic acids, and gene therapies).
Novo Nordisk has over 100 years of expertise developing and commercializing therapeutics in the cardiometabolic and rare disease space. Their deep disease expertise in these areas has allowed Novo Nordisk to launch 19 products globally.
Learn more about Evotec and Novo Nordisk